In this issue of the Scandinavian Journal of Pain, Jarkko Kalliomäki et al. report a negative trial of a chemochine receptor (CCR2) antagonist in painful diabetic neuropathy . This was a relevant trial performed with appropriate methodology and of high quality.1The importance of publishing well done negative outcome trialsThe researchers should be praised for having taken the initiative to publish the results, and it is even more praiseworthy that the initiative stems from a drug company. The journal deserves to be credited for taking up the responsibility to also publish negative results that may not attract so much attention as do positive trials. Publication of high quality negative trials is extremely important because it may have implications for clinical practice and for research strategies within the field, so the limited resources are used most cost-effectively.Most clinicians will probably strive to pursue an evidence-based pharmacological treatment approach for their patients with neuropathic pain. To do so, it is obvious to consult resources such as guidelines and reviews [2,3,4]. These resources will typically have compiled all the relevant published trials within the field. Based on critical review of the trials, an evidence-based recommendation is given and information on the efficacy to
Scandinavian Journal of Pain – de Gruyter
Published: Apr 1, 2013
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera